Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial
청소년 및 노인의 SARS-COV-2 재조합 스파이크 단백질 백신 (NVX-COV2373)의 상이한 용량 요법 : 2 상 무작위 위약 대조 시험
Clinical Trial
[키워드] 95% CI
95% confidence interval
accumulate
addition
Administered
Adults
adverse events
age
Anti-spike
Antibody Response
assessments
assigned
composed
conducted
convalescent sera
coronavirus
Day
dose
dose regimen
Efficacy
Endpoint
Enrollment
exceeded
Follow-up
Formica
Frequency
full-length SARS-CoV-2
geometric mean
geometric mean titer
geometric mean titers
GMTs
group
groups
identify
IgG
immune persistence
immune response
immune responses
immunogenic
immunogenicity
Immunoglobulin
Immunoglobulin G
include
inhibitory concentration
intensity
intramuscular dose
lack
limitation
Matrix-M1 adjuvant
median
Mild
mild to moderate
moderate
neutralizing antibody
Neutralizing antibody response
neutralizing antibody responses
NVX-CoV2373
occurred less
Older
Older adults
participant
Participants
Phase 1
Phase 2
Placebo
placebo-controlled
placebo-controlled trial
primary endpoints
Protein
Randomized
randomized placebo-controlled trial
Randomly
reactogenicity
receive
Recombinant spike protein
regimen
researcher
respiratory
Respiratory Coronavirus
robust
safety follow-up
SARS-CoV-2
second dose
second vaccination
secondary endpoint
seroconversion rate
seroconversion rates
severity
short duration
spike glycoprotein
spike glycoproteins
Spike protein
Support
The United States
These data
Tolerability
Treatment
Trial
Trial registration
trimeric
United States
USA
vaccination
Vaccine
vaccine group
wild-type virus
[DOI] 10.1371/journal.pmed.1003769 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1371/journal.pmed.1003769 PMC 바로가기 [Article Type] Clinical Trial